NMC
ELVN icon

NEA Management Company’s Enliven Therapeutics ELVN Stock Holding History

NEA Management Company’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-251,681
Closed -$1.23M – 58
2022
Q2 		$1.23M Sell
251,681
-575,342
-70% -$2.81M 0.06% 53
2022
Q1 		$6.22M Sell
827,023
-69,570
-8% -$459K 0.18% 47
2021
Q4 		$8.07M Sell
896,593
-107,700
-11% -$1.41M 0.16% 49
2021
Q3 		$16.4M Hold
1,004,293
– – 0.19% 44
2021
Q2 		$31.7M Hold
1,004,293
– – 0.41% 34
2021
Q1 		$33.9M Hold
1,004,293
– – 0.76% 30
2020
Q4 		$88.6M Hold
1,004,293
– – 2.34% 14
2020
Q3 		$81.7M Hold
1,004,293
– – 3.46% 11
2020
Q2 		$111M Hold
1,004,293
– – 4.46% 9
2020
Q1 		$64.4M Buy
+1,004,293
New +$64M 3.36% 13

Other funds holding ELVN

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

NEA Management Company's ELVN Position: Q3 2022 in Review

NEA Management Company sold out of Enliven Therapeutics (ELVN) in Q3 2022, closing a stake of 251,681 shares — an estimated $1.23M sold.

NEA Management Company first reported a position in ELVN in Q1 2020 and held it in 10 quarters. The position peaked at $111M in Q2 2020. 31 funds tracked by Wall St. Rank hold ELVN as of Q3 2022.

  • NEA Management Company reported no remaining Enliven Therapeutics position as of Q3 2022 after selling out during the quarter.
  • NEA Management Company sold 251,681 Enliven Therapeutics shares in Q3 2022, an estimated $1.23M.
  • NEA Management Company first reported a position in Enliven Therapeutics in Q1 2020 and held it in 10 quarters.
  • NEA Management Company's Enliven Therapeutics position peaked at $111M in Q2 2020.
  • 31 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2022.

Based on NEA Management Company's 13F filing for Q3 2022, filed 14 Nov 2022.